Publications
1. Orimo S, Araki M, Ishii H, Ikeda M, Kurosawa T, Arai M,
Hiyamuta E. A case of myopathy with tubular aggregates with increased muscle
fiber sensitivity to caffeine. J Neurol 1987;234:424-426.
2. Ikeda M, Mikuni M, Nishikawa T, Takahashi K. A
neurochemical study of a new mutant mouse presenting myoclonus-like involuntary
movement: a possible model of spontaneous serotonergic hyperactivity. Brain Res
1989;495:337-348.
3. Uchihara T, Ikeda M, Takahashi H, Yoshida S, Tsukagoshi
H. CSF lymphocyte subsets in aseptic meningitis: dual labelling analysis with
flow cytometry. Acta Neurol Scand 1990;81:468-470.
4. Ikeda M, Tsukagoshi H. Encephalopathy due to toluene
sniffing, Report of a case with magnetic resonance imaging. Eur Neurol
1990;30:347-349.
5. Kurumaji A, Ikeda M, Dewar D, McCormac AG, McCulloch J.
Effects of chronic administration of MK-801 upon local cerebral glucose
utilization and ligand binding to the NMDA receptor complex. Brain Res
1991;563:57-65.
6. Uchihara T, Ikeda M, Tsukagoshi H. Recurrent Fisher's syndrmoe
with immunological abnormalities and replicated laterality. Eur Neurol
1991;31:270-272.
7. Ikeda M, Dewar D, McCulloch J. Selective reduction of
[125I]-apamin binding sites in Alzheimer hippocampus, A quantitative
autoradiographic study. Brain Res 1991;567:51-56.
8. Ikeda M, Dewar D, McCulloch J. Preservation of
[125I]-galanin binding sites despite loss of cholinergic neurones in
Alzheimer's disease. Brain Res 1991;568:303-306.
9. Ikeda M, Tsukagoshi H. Monochorea caused by striatal
lesion. Eur Neurol 1991;31:257-258.
10. Ikeda M, Tsukagoshi H. Vogt-Koyanagi-Harada disease
presenting meningoencephalitis, Report of a case with magnetic resonance
imaging. Eur Neurol 1992;32:83-85.
11. Ikeda M, Yoshida S, Tsukagoshi H. Interferon-g in
cerebrospinal fluid without pleocytosis in scrub typhus. J Neurol Sci
1992;109:61-63.
12. Ikeda M, Dewar D, McCulloch J. A correlative study of
calcium channel antagonist binding and local neuropathological features in the
hippocampus in Alzheimer's disease. Brain Res 1992;589:313-319.
13. Sato I, Morita I, Kaji K, Ikeda M, Nagao M, Murota S.
Reduction of nitric oxide producing activity associated with aging in cultured
human umbilical vein endothelial cells. Biochem Biophys Res Commun
1993;195:1070-1076.
14. Ikeda M, Dewar D, McCulloch J. High affinity
hippocampal [3H]-glibenclamide binding sites are preserved in Alzheimer's
disease. J Neural Transm [P-D Sect] 1993;5:177-184.
15. Ikeda M, Morita I, Murota S, Sekiguchi F, Yuasa T,
Miyatake T. Cerebellar nitric oxide synthase activity is reduced in nervous and
Purkinje cell degeneration mutants but not in climbing fiber-lesioned mice.
Neurosci Lett 1993;155:148-150.
16. Ikeda M, Dewar D, McCulloch J. Differential alterations
of ion channel binding sites in temporal and occipital regions of the cerebral
cortex in Alzheimer's disease. Brain Res 1993;630:50-56.
17. Ikeda M, Mackay KB, Dewar D, McCulloch J. Differential
alterations in adenosine A1 and k1 opioid receptors in the striatum in
Alzheimer's disease. Brain Res 1993;616:211-217.
18. Ikeda M, Matsui K, Ishihara Y, et al. Cerebellar nitric
oxide synthase, cGMP and motor function in two lines of cerebellar mutant mice,
Staggerer and Wriggle Mouse Sagami. Neurosci Lett 1994;168:65-68.
19. Ikeda M, Takahashi K, Matsunaga T, Tsukagoshi H. Reversible
white matter lesions in a patient with fulminant hepatitis and acute renal
failure. Intern Med 1994;33:360-362.
20. Ikeda M, Takahashi H, Yoshida S. HLA-DR+CD3+ and CD8+
cells are increased but CD4+CD45RA+ cells are reduced in the peripheral blood
in human scrub typhus. Clin Immunol Immunopathol 1994;72:402-404.
21. Komachi H, Tsuchiya K, Ikeda M, Koike R, Matsunaga T,
Ikeda K. Radiation myelophathy: a clinicopathological study with special
reference tjo correlation between MRI findings and neuropathology. J Neurol Sci
1995;132:228-232.
22. Ikeda M, Dewar D, McCulloch J. Galanin receptor binding
sites in the temporal and the occipital cortex are minimally affected in
Alzheimer's disease. Neurosci Lett 1995;192:37-40.
23. Ikeda M, Sato I, Yuasa T, Miyatake T, Murota S.
Nitrite, nitrate and cGMP in the cerebrospinal fluid in degenerative neurologic
diseases. J Neural Transm [Gen Sect] 1995;100:263-267.
24. Ikeda M, Sato I, Matsunaga T, Takahashi M, Yuasa T,
Murota S. Cyclic guanosine monophosphate (cGMP), nitrite and nitrate in the cerebrospinal fluid in meningitis,
multiple sclerosis and Guillain-Barré syndrome. Intern Med
1995;34:734-737.
25. Himi T, Ikeda M, Sato I, Yuasa T, Murota S. Purkinje
cells express neuronal nitric oxide synthase after methylmercury
administration. Brain Res 1996;718:189-192.
26. Ikeda M, Kanai H, Akaike M, et al. Nitric oxide
synthase-containing neurons in the hippocampus are preserved in trimethyltin
intoxication. Brain Res 1996;712:168-170.
27. Ikeda M, Komachi H, Sato I, Himi T, Yuasa T, Murota S.
Induction of neuronal nitric oxide synthase by methylmercury in the cerebellum.
J Neurosci Res 1999;55:352-356.
28. Ikeda M, Komiyama T, Sato I, Himi T, Murota S. Neuronal
nitric oxide synthase is resistant to ethanol. Life Sci
1999;64:1623-1630.
29. Tsuchiya K, Ozawa E, Haga C, Watabiki, S, Ikeda M, Sano
M, Ooe K, Taki K, Ikeda, K. Constant involvement of the Betz cells and
pyramidal tract in multiple system atrophy: a clinicopathological study of
seven autopsy cases. Acta Neuropathol 2000;99: 628-636
30. Suzuki R, Ikeda M, Kami M. Japanese physicians and
public respect. Lancet 2000;356:598-600.
31. Ikeda M and Yoshida S. HIV-1 and scrub typhus. Lancet 2000;356:1851.
32. Ikeda M. Iron overload without the C282Y mutation in patients with epilepsy. J Neurol Neurosurg Psychiat 2001;70:551-3.
33. Ikeda M. Arai Y. Longitudinal changes in brain CTscans
and development of dementia in Down's syndrome. Eur Neurol
2002;47:205-208
34. Ikeda M, MatsunagaT, Irabu N, Yoshida S. Using
vital signs to diagnose impaired consciousness: cross sectional observational
study. BMJ 2002;325:800
35. Himi T, Ikeda M, Yasuhara T, Murota S. Oxidative
neuronal death caused by glutamte uptake inhibition in cultured hippocampal
neurons. J Neurosci Res 2003;71:679-688
36. Himi T, Ikeda M, Yasuhara T, Morita I. Role of Neuronal
Glutamate Transporter in the Cysteine Uptake and Intracellular Glutathione
Levels in Cultured Cortical Neurons. J Neural Transm [Gen Sect] 2003;110:
1337-48
37. Kishi Y, Miyakoshi S, Kami M, Ikeda M, Katayama
Y, Murashige N, Kusumi E, Yuji K, Kobayashi K, Kato D, Hamaki T, Matsumura
T, Kim S-W, Morinaga , Mori S, Kanemaru M, Hayashi T, Takaue Y, Taniguch
S. Early central nervous system complication following reduced intensity
stem-cell transplantation. Biol Blood Marrow Transplant 2004;10:561-568
38. Ikeda M. Family bias by proxy. Lancet 2005;365:187
39. Kobayashi K, Kami M, Ikeda M, Kishi Y, Murashige N, Tanosaki R, Mori S, Takaue Y.
Fulminant septicemia caused by Bacillus cereus following reduced-intensity
umbilical cord blood transplantation. Haematologica 2005;90:ECR06
40. Murashige N, Kami M, Ikeda M. Aspirin, COX-2, and the
Risk of Colorectal Cancer. N Engl J Med 2007;357: 824.
41. Kondoh T, Kanno A, Itoh H, Nakashima M, Honda R, Kojima M,
Noguchi M, Nakane H, Nozaki H, Sasaki H, Nagai T, Kosaki R, Kakee N, Okuyama T,
Fukuda M, Ikeda M, Shibata Y, Moriuchi H. Donepezil Significantly
Improves Abilities in Daily Lives of Female Down Syndrome Patients with Severe
Cognitive Impairment: A 24-Week Randomized, Double-Blind, Placebo-Controlled
Trial. Int J Psychiatry Med 2011;41:71-89.
42. Shimazawa R, Ikeda M. Japan lags behind the UK in
neurological drug approvals. Br J Clin Pharmacol 2011;71:473-475.
43. Ikeda M. Fulminant form
of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like
episodes: A diagnostic challenge. J Med Cases 2011;2(2):87-90.
44. Shimazawa R, Ikeda M. Delays in neurological drug
development in Japan. Internal Medicine 2011;50:1565-1568.
45. Shimazawa R, Ikeda M. Medical management of the acute
radiation syndrome. Ann Intern Med 2011;155:135-6.
46. Shimazawa R, Ikeda M. Development of drugs against
chemical, biological, radiological, or nuclear agents. Lancet 2011;378:486.
47. FujiwaraT, Nishimura M, Honda R, Nishiyama T, Nomoto M,
Kobayashi N, Ikeda M. Comparison of peer-led versus professional-led
training in basic life support for medical students. Advances in Medical
Education and Practice 2011;2:187–191.
48. Shimazawa R, Kusumi I, Ikeda M. Delays in psychiatric
drug development in Japan. J Clin Pharm Ther 2012;37:348-351.
49. Shimazawa R, Ikeda M. The vaccine gap between Japan
and the UK. Health Policy 2012;107:312-317
50. Shimazawa R, Ikeda M.Japanese regulatory system for
approval of off-label drug use: Evaluation of safety and effectiveness in
literature-based applications. Clin Ther 2012;34:2104-16
51. Shimazawa R, Ikeda M. Are there any differences in
the regulations of personalised medicine among the US, EU, and Japan? Br J Clin
Pharmacol 2313;75: 1365-7
52. Asakura T, Kodera S, Kanda J, Ikeda M.
Thiamine-responsive pulmonary hypertension. BMJ Case Reports 2013; doi:10.1136/bcr-2012-007938
53. Shimazawa R, Ikeda M. Safety information in drug
labeling: a comparison of the United States, the United Kingdom, and Japan.
Pharmacoepidemiol Drug Saf 2013;22:306-18
54. Shimazawa R, Ikeda M. Differences in pharmacogenomic
biomarker information in package inserts from the United States, the United
Kingdom, and Japan. J Clin Pharm Ther 2013;38:468–475
55. Shimazawa R, Ikeda M.
Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics
between the United States and Japan. J Clin Pharm Ther 2014;39:210-214
56. Kodera
S, Ikeda M, Sato K, Kushida S, Kanda J. Percutaneous coronary
intervention is a useful bridge treatment for acute myocardial infarction due
to acute type A aortic dissection. Cardiovasc Interv Ther. 2014 Apr 2. [Epub ahead
of print]
57. Shimazawa R, Ikeda M. Conflicts of interest in
psychiatry: strategies to cultivate literacy in daily practice. Psychiatry Clin
Neurosci 2014;68:489–497
58. Asakura T, Ikeda M, Nakamura A, Kodera S. Efficacy of
empirical therapy with non-carbapenems for urinary tract infections with
extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Infect Dis
2014;21:91-95
59. Shimazawa R, Ikeda M. International differences in
companion diagnostic approvals: How are we able to manage the differences?
Expert Rev Mol Diagn 2015;15:157-159 (doi:10.1586/14737159.2015.969243)
60. Shimazawa R, Ikeda M. Development of drug-approval
regulations to medical countermeasures against chemical, biological,
radiological, or nuclear agents in Japan. Health Security. 2015;13:130-138.
doi:10.1089/hs.2014.0068
61. Kawasaki K, Miyaji K, Kodera S, Suzuki Y, Kanda J, Ikeda
M. Arrhythmogenic right ventricular cardiomyopathy in a patient with
schizophrenia. Clinical Case Reports 2015; 3(5): 308–314 (DOI: 10.1002/ccr3.230)
62. Aoki
Y, Kodera S, Shakya S, Ishiwaki H, Kanda J, Ikeda M. Isolated deep T
wave inversion on an electrocardiogram with normal wall motion.
Clinical Case Reports 2015; 3(7): 594–597 (doi: 10.1002/ccr3.242)
63. Shimazawa R, Ikeda M.
Overcoming regulatory challenges in the development of companion
diagnostics for monitoring and safety. Per Med 2016;13(2):155-67
64. Shimazawa R, Ikeda M.
Drug–diagnostic co-development: challenges and issues. Expert Review of
Molecular Diagnostics 2016;16(2):187-204
DOI:10.1586/14737159.2016.1132163
65. Shimazawa R, Ikeda M.
Approval status and evidence for WHO essential medicines for children
in the United States, United Kingdom, and Japan: a cross-sectional
study. J Pharm Policy Pract 2017;10:4 DOI : 10.1186/s40545-016-0094-2.
66. Todaka K, Kishimoto J, Ikeda M,
Ikeda K, Yamamoto H. Impact of Risk-Benefit Perception and Trust on
Medical Technology Acceptancein Relation to Drug and Device Lag:A
Tripartite Cross-Sectional Survey. Ther Innov Regul Sci 2018;52:629-640.
67. Shimazawa R, Ikeda M. Pharmacogenomic
biomarkers on drug labels: interpretation of United States and Japanese
labels based on Pharmacogenetics Knowledgebase. J Clin Pharm
Ther 2018;43:500–506
68. Shimazawa R, Kano Y, Ikeda M.
Natural language processing-based assessment of consistency in
summaries of product characteristics of generic antimicrobials. Pharmacol Res Perspect 2018;6:e00435.
69. Ikeda
M, Shimazawa R. Challenges to hemoglobin A1c as a therapeutic target
for type 2 diabetes mellitus. J Gen Fam Med 2019;20:129-38
70. Shimazawa R, Ikeda M.
Chapter 19. Regulatory requirements for companion diagnostics – Japan.
In: Jan Trøst Jørgensen, eds. Companion and Complementary Diagnostics
From Biomarker Discovery to Clinical Implementation. 1st ed. Amsterdam:
Elsevier; 2019. p. 365-379.
71. Shimazawa R, Ikeda M.
Chapter 9. Clinical Trial Designs for Testing Companion Diagnostics.
In: Il-Jin Kim, ed. Companion Diagnostics (CDx) in Precision Medicine.
Singapore: Jenny Stanford Publishing; 2019.
72. Shimazawa R, Ikeda M.
Imbalance in glycemic control between the treatment and placebo groups
in cardiovascular outcome trials in type 2 diabetes. J Pharm Policy
Pract 2019;12:30.
73. Shiamazawa R. Ikeda M.
Regulatory perspectives on next-generation sequencing and complementary
diagnostics in Japan. Expert Rev Mol Diagn 2020;1-10. doi:
10.1080/14737159.2020.1728256
74. Shiamazawa R. Ikeda M.
Approvals of type 2 diabetes drugs tested in cardiovascular outcome
trials: A tripartite comparison. Br J Clin Pharmacol. 2021 Oct;87(10):3938-3948. doi:
10.1111/bcp.14814.
75. Shimazawa, R., Ikeda, M.
Potential adverse events in Japanese women who received tozinameran
(BNT162b2, Pfizer-BioNTech). J Pharm Policy Pract 14, 46 (2021).
https://doi.org/10.1186/s40545-021-00326-7.
76. Fujita Y, Morimoto T, Tokushige A, Ikeda M,
Shimabukuro M, Node K, Ueda S. Women with type 2 diabetes and coronary
artery disease have a higher risk of heart failure than men, with a
significant gender interaction between heart failure risk and risk
factor management: a retrospective registry study. BMJ Open Diabetes
Res Care. 2022;10:e002707. doi: 10.1136/bmjdrc-2021-002707.
77. Ikehara Y, Morimoto T, Ikeda M, Node K, Ueda S. Errors identified by early, risk-adapted, triggered on-site monitoring in physician-initiated clinical trials not for regulatory approval in cardiovascular diseases. Jpn J Clin Pharmacol Ther 2023;54:9‒16.
78. Yamauchi Y, Miwa Y, Ikeda M,
Ueda S. Comparison of the quality of phase III non-commercial clinical
trials in Japan, the United States, and the United Kingdom before the
implementation of the new Japanese Clinical Trials Act. Jpn J Clin
Pharmacol Ther 2023;54:95-101. https://doi.org/10.3999/jscpt.54.3_95
Massie's Home